Spinal injection to prevent nerve side effects from CAR-T therapy
Treatments studied
Part of Blood & lymphatic, Brain & nervous system, Cancer clinical trials.
This trial tests if a spinal injection of three common chemotherapy drugs can reduce or prevent serious brain and nerve side effects in people receiving CAR-T cell therapy for cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You are scheduled to receive the CAR-T drugs Yescarta or Tecartus in the hospital.
- You must be generally active and able to care for yourself (ECOG performance status 0–2).
- Your blood platelet count must be above 50,000, and your clotting tests must be normal.
- You cannot have active cancer in the brain or spinal cord, a history of certain brain disorders, or a bleeding problem.
- You must agree to use birth control for 30 days after CAR-T therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses blood tests and brain imaging to better understand and predict nerve-system side effects that can happen after CAR T-cell treatment. It may help doctors spot people at higher risk sooner and guide safer care.
This study looks at how your immune system responds to CAR-T cell therapy, a treatment that uses your own immune cells to fight certain cancers. By participating, you help researchers learn more about how this therapy affects the body, which could improve care for future patients.
This trial tests a new immune-cell therapy (CAR-T) for people with certain autoimmune diseases of the brain and spinal cord that have not improved with standard treatments. The therapy aims to reset the immune system to stop it from attacking the nervous system.
This trial adds a small, whole-body dose of radiation to the standard preparation before CAR-T cell therapy (tisagenlecleucel). The goal is to improve the treatment's effectiveness for patients with relapsed or refractory large B-cell lymphoma.
This Phase 1 study tests a new type of immune therapy (CAR T cells) placed directly into the fluid around the brain to treat central nervous system (CNS) lymphoma. It mainly looks at safety and how well the treatment can control the lymphoma when other CNS treatments have not worked.
This study is for people getting CAR-T cell therapy, a type of cancer treatment that uses your own immune cells. Researchers want to understand a rare side effect called neurotoxicity by looking at tiny particles in your blood called extracellular vesicles.
Hear when a new Hematopoietic and Lymphatic System Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.